Skip to main content

Preclinical Evaluation of Therapeutic Compounds in Mouse Models for Cancer at the Center for Advanced Preclinical Research (CAPR)

Friday, September 15, 2017 — Poster Session IV

1:00 p.m. – 2:30 p.m.
FAES Terrace


  • Ludmila Szabova
  • Rajaa El Meskini
  • Tomas Vilimas
  • Baktiar Karim
  • Stephen Jones
  • Shyam Sharan
  • Serguei Kozlov
  • Zoe Weaver Ohler


The Center for Advanced Preclinical Research (CAPR) is a CCR-supported resource to carry out in vivo preclinical research using well characterized mouse cancer models. Its mission is to develop, disseminate, and apply reproducible preclinical practices effective in guiding clinical research toward improved cancer patient outcomes. We partner with Leidos and CCR core facilities to achieve a broad range of capabilities (e.g. efficacy studies; required for effective preclinical cancer research. The goal is to evaluate preclinical compounds or existing drugs or biologics (therapeutics) for the identification of new indications or new combinations or sequences of dosing using genetically engineered mouse (GEM) models and GEM-derived allograft (GDA). GEM models of cancer recapitulate the tumor microenvironment, including the intact immune response, more accurately and produce more representative tumors than classic human cell line xenograft models. For comparison, we also establish patient-derived xenografts in collaboration with NCI Investigators. Since its inception, CAPR has been collaborating with academic and NCI investigators, as well as foundations and pharmaceutical companies, to perform preclinical studies in glioblastoma, melanoma, lung, ovarian, and pancreatic cancers.

With increasing interest of CCR investigators to partner with CAPR, the CAPR Oversight Committee (OC) was established by CCR leadership at the end of 2015, and CAPR Request for Application (RFA) was announced to CCR research community in summer of 2016 and 2017. The purpose is to support rigorous, preclinical studies in mouse models with the goal of establishing the rationale for translation of preclinical findings to pre-Phase I or Phase I clinical studies.

Category: Cancer Biology